CEACAM5 and neoplasm: To achieve a better prognosis, imaging (39, 40), carcinoembryonic antigen (CEA) combined with carbohydrate antigen 19-9 (CA19-9) (41), platelet-associated biomarkers (42), and circulating tumor DNA (ctDNA) (43) must be dynamically estimated and promptly evaluated.